.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
McKesson
Fish and Richardson
Federal Trade Commission
Julphar
Johnson and Johnson
Boehringer Ingelheim
US Department of Justice
Cantor Fitzgerald
UBS

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,333,310

« Back to Dashboard

Which drugs does patent 9,333,310 protect, and when does it expire?


Patent 9,333,310 protects ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, INCRUSE ELLIPTA , and TRELEGY ELLIPTA, and is included in five NDAs.

This patent has sixteen patent family members in sixteen countries.

Summary for Patent: 9,333,310

Title:Medicament dispenser
Abstract: A sheet driver for use in a medicament dispenser with blister pockets includes: (a) a base, extending from the base, (b) a shaft defining a rotational axis; at the base, (c) a drive surface for receipt of drive to rotate the base about the rotational axis; about the shaft, (d) a torsion spring defining first and second spring legs; mounting about the shaft and the torsion spring for rotation about the rotational axis, and (e) a hub defining a hub surface for receipt of a sheet of the medicament carrier, the hub surface being adapted to provide an initial effective winding surface which provides uniform indexing of the medicament carrier.
Inventor(s): Jones; Christopher John (Warwick, GB), May; James John (Warwick, GB), Lintell; Daniel Thomas De Sausmarez (Ware, GB), Palmer; Mark Gregory (Ware, GB), Tansley; Robert William (Bidford on Avon, GB)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:13/483,168
Patent Claim Types:
see list of patent claims
Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes► Subscribe► Subscribe► SubscribeY
Glaxo Grp EnglandINCRUSE ELLIPTA umeclidinium bromidePOWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
GlaxosmithklineTRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION209482-001Sep 18, 2017RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,333,310

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0418278.8Aug 16, 2004

Non-Orange Book Patents for Patent: 9,333,310

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,201,556Medicament dispenser► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,333,310

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico2007001956► Subscribe
Japan4960868► Subscribe
Japan2008509766► Subscribe
HungaryE028513► Subscribe
Hong Kong1106169► Subscribe
United Kingdom0418278► Subscribe
Spain2561421► Subscribe
European Patent Office1786498► Subscribe
Denmark1786498► Subscribe
Cyprus1117205► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Medtronic
Farmers Insurance
Novartis
Boehringer Ingelheim
Fuji
Queensland Health
Healthtrust
Mallinckrodt
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot